For example, biomarker analyses of the BERIL-1 trial showed that patients with squamous cell carcinoma of the head and neck, who also had TP53 alterations, benefited from the combination of buparlisib and paclitaxel in terms of survival [43]. This evidence concerns the gene TP53 and squamous cell carcinoma.